Association of high levels of plasma free dopamine with future coronary events in patients with coronary artery disease

Circulation Journal

Volumn 71, Issue 5, 2007, Pages 688-692

  Abe, Makoto ^a   Iwaoka, Masahiko ^a   Nakamura, Takamitsu ^a   Kitta, Yoshinobu ^a   Takano, Hajime ^a   Kodama, Yasushi ^a   Kawabata, Kenichi ^a   Obata, Jyun Ei ^a   Mende, Akira ^a   Kobayashi, Tsuyoshi ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Hasebe, Hideyuki ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Coronary artery disease; Dopamine; Inflammation; Prognosis; Risk factors

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DOPAMINE; FIBRINOGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOPAMINE BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGNOSIS;

AGED; C-REACTIVE PROTEIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DOPAMINE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 34247581369     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.688     Document Type: Article

References (32)

1. Anfossi G, Massucco P, Mularoni E, Cavalot F, Burzacca S, Mattiello L, et al. Studies on the effect of dopamine on the human platelet response. Clin Exp Pharmacol Physiol 1992; 19: 613-618.
2. Braunstein KM, Sarji KE, Kleinfelder J, Schraibman HB, Colwell JA, Eurenius K. The effects of dopamine on human platelet aggregation, in vitro. J Pharmacol Exp Ther 1977; 200: 449-457.
3. Anderson KP. Sympathetic nervous system activity and ventricular tachyarrhythmias: Recent advances. Ann Noninvasive Electrocardiol 2003; 8: 75-89.
4. Oyama N, Urasawa K, Kaneta S, Sakai H, Saito T, Takagi C, et al. Chronic beta-adrenergic receptor stimulation enhances the expression of G-protein coupled receptor kinases, GRK2 and GRK5, in both the heart and peripheral lymphocytes. Circ J 2005; 69: 987-990.
5. Nonomura M, Nozawa T, Matsuki A, Nakadate T, Igarashi N, Kato B, et al. Ischemia-induced norepinephrine release, but not norepinephrine-derived free radicals, contributes to myocardial ischemia-reperfusion injury. Circ J 2005; 69: 590-595.
6. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988; 84: 61-66.
7. Snider SR, Kuchel O. Dopamine: An important neurohormone of the sympathoadrenal system: Significance of increased peripheral dopamine release for the human stress response and hypertension. Endocr Rev 1983; 4: 291-309.
8. Viquerat CE, Daly P, Swedberg K, Evers C, Curran D, Parmley WW, et al. Endogenous catecholamine levels in chronic heart failure: Relation to the severity of hemodynamic abnormalities. Am J Med 1985; 78: 455-460.
9. Van Loon GR. Plasma dopamine: Regulation and significance. Fed Proc 1983; 42: 3012-3018.
10. Nakagawa K, Umetani K, Fujioka D, Sano K, Nakamura T, Kodama Y, et al. Correlation of plasma concentrations of B-type natriuretic peptide with infarct size quantified by tomographic thallium-201 myocardial scintigraphy in asymptomatic patients with previous myocardial infarction. Circ J 2004; 68: 923-927.
11. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 2006; 48: 43-50.
12. Yoshimura M, Komori T, Nakanishi T, Takahashi H. Estimation of sulphoconjugated catecholamine concentrations in plasma by high-performance liquid chromatography. Ann Clin Biochem 1993; 30: 135-141.
13. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-246.
14. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-689.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-S20.
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
17. Kopin IJ. Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 1985; 37: 333-364.
18. Ozawa Y, Yoshizumi M, Inui D, Tsuchiya K, Houchi H, Tamaki T, et al. Plasma levels of free and sulfoconjugated catecholamines in patients with atherosclerosis. Biol Pharm Bull 1999; 22: 657-659.
19. Wang PC, Buu NT, Kuchel O, Genest J. Conjugation patterns of endogenous plasma catecholamines in human and rat: A new specific method for analysis of glucuronide-conjugated catecholamines. J Lab Clin Med 1983; 101: 141-151.
20. Huq AH, Matsuoka S, Kurahashi Y, Kuroda Y, Ma SJ, Ohuchi T, et al. Dopamine 4-sulfate: Effects on isolated perfused rat heart and role of atria. Life Sci 1988; 43: 1599-1606.
21. Yoshizumi M, Ishimura Y, Masuda Y, Ohuchi T, Katoh I, Houchi H, et al. Physiological significance of plasma sulfoconjugated dopamine: Experimental and clinical studies. Hypertens Res 1995; 18: S101-S106.
22. Dobnig H, Leb G, Lipp R, Porta S, Dusleag J, Eber B, et al. Sulfo-conjugated and free plasma catecholamine levels at rest and during exercise in patients with idiopathic dilated cardiomyopathy. Eur J Endocrinol 1995; 132: 181-191.
23. Kostulak A. The effect of ACTH and cortisone on the behaviour of arylsulphatases in the salivary glands of white rat. Acta Histochem 1977; 58: 63-67.
24. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction: SOLVD investigators. Circulation 1996; 94: 690-697.
25. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
26. Isnard R, Pousset F, Trochu J, Chafirovskaia O, Carayon A, Golmard J, et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000; 86: 417-421.
27. Carruthers M, Conway N, Somerville W, Taggart P, Bates D. Validity of plasma-catecholamine estimations. Lancet 1970; 1: 62-67.
28. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of Creactive protein in risk assessment. Am J Med 2004; 116: 9s-16s.
29. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 2006; 114: 381-387.
30. Crea F, Chierchia S, Kaski JC, Davies GJ, Margonato A, Miran DO, et al. Provocation of coronary spasm by dopamine in patients with active variant angina pectoris. Circulation 1986; 74: 262-269.
31. Lokhandwala MF, Barrett RJ. Cardiovascular dopamine receptors: Physiological, pharmacological and therapeutic implications. J Auton Pharmacol 1982; 2: 189-215.
32. Schomig A, Richardt G. Cardiac sympathetic activity in myocardial ischemia: Release and effects of noradrenaline. Basic Res Cardiol 1990; 85: 9-30.